1 min read
Larimar Therapeutics Estimates $128.7 Million in Cash at Quarter-End
The preliminary, unaudited estimate covers cash, equivalents and marketable securities as of Sept. 30, 2026. Larimar projects its cash runway into late Q2 2027.

Larimar Therapeutics, Inc. estimated it had $128.7 million in cash, cash equivalents and marketable securities at the end of September, with a projected cash runway into late Q2 2027.
The figure was preliminary and unaudited as of Sept. 30, 2026, and could change after the quarter-end close.
Larimar’s cash runway projection extends into late Q2 2027.